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The endocrine-disrupting potential of persis-
tent organic pollutants (POPs) such as organo-
chlorine pesticides, polychlorinated biphenyls
(PCBs), and polychlorinated dibenzo-p-
dioxins/dibenzofurans (PCDDs/PCDFs) has
received significant attention since the early
1990s. These endocrine-disrupting chemicals
(EDCs) have the potential to mimic, enhance,
or antagonize the biological activity of endoge-
nous hormones and thereby interfere with the
development and function of the immune,
reproductive, and central nervous systems,
and thus the cognitive development in ani-
mals and humans (Ahmed 2000; Bonefeld-
Jørgensen 2004; Bonefeld-Jørgensen and
Ayotte 2003; Hotchkiss et al. 2002; Jacobson
and Jacobson 1996; McLachlan et al. 2001;
Patandin et al. 1999). The use of many
organochlorine pesticides and PCBs has been
restricted or banned since the 1970s in most
industrialized countries, but their lipophilic
and persistent nature cause bioaccumulation
and magnification in the marine food web
and piscivorous birds (Dewailly et al. 1993),
and thus continue to be a potential health
threat to wildlife and humans. POPs are glob-
ally ubiquitous due to long-range transport by
atmospheric and oceanic currents and are
found in, for example, Arctic areas (Barrie et al.
1992; Macdonal et al. 2000). Many PCB con-
geners, PCDDs/PCDFs, and pesticides [e.g.
2,2-bis(p-chlorophenyl)-1,1,1-trichloroethane
(DDT) and its main metabolite 1,1-dichloro-
2,2-bis(p-chlorophenyl)-ethylene (p,p´-DDE)]
have been found in human blood, adipose tis-
sue, and breast milk (Archibeque-Engle et al.
1997; Bonefeld-Jørgensen and Ayotte 2003;
Turusov et al. 2002). 
The androgen receptor (AR) is the key reg-
ulatory element of androgen cell signaling and
is essential for male reproductive functions and
development, including spermatogenesis
(Sharpe 2006). Antagonistic effects on the AR
activity in vitro have been reported for several
pesticides including p,p´-DDE (Kelce et al.
1995), dieldrin (Andersen et al. 2002; Roy
et al. 2004), fenarimol (Andersen et al. 2002),
methiocarb (Andersen et al. 2002; Birkhoj
et al. 2004), prochloraz (Andersen et al.
2002; Birkhoj et al. 2004; Vinggaard et al.
2002), and vinclozolin (Kelce et al. 1994).
Furthermore, several PCB congeners (CBs 49,
66, 74, 77, 105, 118, 126, 138, 153, and 156)
have been reported to act as AR antagonists
(Bonefeld-Jørgensen et al. 2001; Endo et al.
2003; Schrader and Cooke 2003). 
During recent years there has been a con-
cern regarding a possible time-related deterio-
ration of human sperm production and a
concomitant increase in the incidence of tes-
ticular germ cell cancer and congenital abnor-
malities of male reproductive organs, such as
hypospadias and cryptorchidism (Huyghe
et al. 2003; Manson and Carr 2003;
Skakkebaek 2003; Toppari 1996; Vidaeff and
Sever 2005). Virtanen et al. (2005) suggested
that the so-called testicular dysgenesis syn-
drome (poor sperm counts, testicular cancer,
hypospadias, and cryptorchidism) is the result
of genetic predisposition combined with cer-
tain environmental- and lifestyle–related
exposures, including EDCs. Many POPs
have shown hormone-disrupting activities in
experimental studies, and prenatal animal
exposures to pesticides, PCBs, and p,p´-DDE
clearly have shown reproductive disruptive
effects, including decreased sperm quality and
malformations (Gray et al. 1999, 2000; Kelce
et al. 1997; Kitamura et al. 2003; Shono et al.
2004). 
This article is part of the monograph “Endocrine
Disruptors—Exposure Assessment, Novel End
Points, and Low-Dose and Mixture Effects.”
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BACKGROUND: Animal and in vitro studies have indicated that human male reproductive disorders
can arise as a result of disrupted androgen receptor (AR) signalling by persistent organic pollutants
(POPs). Our aim in the present study was to compare serum xenoandrogenic activity between
study groups with different POP exposures and to evaluate correlations to the POP proxy markers
2,2´,4,4´,5,5´-hexachlorobiphenyl (CB-153) and 1,1-dichloro-2,2-bis(p-chlorophenyl)-ethylene
(p,p´-DDE). 
METHODS: We determined xenoandrogenic activity in the serum fraction containing the lipophilic
POPs but free of endogenous hormones. Adult male serum (n = 261) from Greenland, Sweden,
Warsaw (Poland), and Kharkiv (Ukraine) was analyzed. Xenoandrogenic activity was determined as
the effect of serum extract alone (XAR) and in the presence of the synthetic AR agonist R1881
(XARcomp) on AR transactivated luciferase activity. 
RESULTS: The study groups differed significantly with respect to XARcomp activity, which was
increased in the Inuits and decreased in the European study groups; we observed no difference for
XAR activity. We found the highest level of the AR antagonist p,p´-DDE in Kharkiv, and accord-
ingly, this study group showed the highest percent of serum samples with decreased XARcomp
activities. Furthermore, the percentage of serum samples with decreased XARcomp activities fol-
lowed the p,p´-DDE serum level for the European study groups. No correlations between serum
XAR or XARcomp activities and the two POP markers were revealed. 
CONCLUSIONS: The differences in XARcomp serum activity between the study groups suggest dif-
ferences in chemical exposure proﬁles, genetics, and/or lifestyle factors. 
KEY WORDS: AR activity, CB-153, human serum, polychlorinated biphenyls, p,p´-DDE. Environ
Health Perspect 115(suppl 1):21–27 (2007). doi:10.1289/ehp.9353 available via http://dx.doi.org/
[Online 8 June 2007]The combined effects of the large number
of environmental contaminants present in
human and wildlife are unexplored. Studies
on the combined effects of some estrogenic
and antiandrogenic chemicals performed
in vitro and in rats (Birkhoj et al. 2004; Gray
et al. 2001, 2004; Hotchkiss et al. 2004;
Nellemann et al. 2003; Payne et al. 2001)
have shown that the combined effects of sin-
gle compounds of low potency cannot be
ignored. In fact, Rajapakse et al. (2002)
showed in vitro that xenoestrogen mixtures
below their no observed effect concentration
caused a dramatic additive enhancement of
hormone actions. 
The present study is part of a large
collaborative research project, INUENDO,
funded by the European Union Commission
with the overall aim to estimate the impact of
POP exposure on human fertility. Cohorts
were established in three European countries—
Sweden, Poland, and Ukraine—together
with cohorts of Inuits from Greenland.
2,2´,4,4´,5,5´-Hexachlorobiphenyl (CB-153)
and p,p´-DDE were used as proxy biomarkers
of exposure to POPs. The speciﬁc aim of the
present study was to determine the actual lev-
els of xenoandrogenic activity in the serum
fractions containing lipophilic POPs but free
of endogenous hormones, and to evaluate
whether xenoandrogenic activity was associ-
ated with the two POP proxy markers. We
used the AR-mediated chemically activated
luciferase expression (AR-CALUX) bioassay
to assess the integrated biological activity of
AR-active lipophilic POP compounds in their
actual mixture in serum.
Xenoestrogenic activity in human adipose
tissue and the serum POP fraction free of
endogenous hormones have previously been
described (Bonefeld-Jørgensen et al. 2006;
Fernandez et al. 2004; Ibarluzea et al. 2004;
Rasmussen et al. 2003; Rivas et al. 2001), and
total androgenic bioactivity has been measured
in whole human serum, including endogenous
hormones (Paris et al. 2002; Raivio et al.
2001; Roy et al. 2006). However, the present
study is, to our knowledge, the ﬁrst report of
the actual xenoandrogenic activity of the
lipophilic POP faction of human serum. Our
hypothesis was that xenoandrogenic activity
would differ between study groups because of
different exposure profiles and that the
selected POP proxy markers would correlate
to the xenoandrogenic activities.
Methods
Study population and collection of blood
samples. Subjects for the main INUENDO
study were recruited among pregnant women
and their male spouses from May 2002
through February 2004 in 19 cities and set-
tlements in Greenland, in Warsaw (Poland),
and in Kharkiv (Ukraine) (Toft et al. 2005). In
addition to the pregnant couples, an already
established cohort of ﬁshermen from Sweden
(Rignell-Hydbom et al. 2005) was included.
Altogether, 798 men provided semen and
blood samples. In the present study, we ana-
lyzed serum samples from a subset of the
INUENDO study groups, consisting of
261 adult males (37 Inuits from Greenland,
83 men from Warsaw, 59 from Sweden, and
82 from Kharkiv). We had intended to ana-
lyze 400 serum samples of high/low POP
exposure; however, in some cases too little
blood was collected for the analysis. Because of
time limitations, the serum samples were ran-
domly selected before POP determination.
The study was approved by the local ethical
committees representing all participating
populations, and all subjects gave written or
oral informed consent. Venous blood samples
were collected into 10-mL vacuum tubes; after
centrifugation, serum samples were transferred
to brown glass bottles (Termometerfabriken,
Gothenburgh, Sweden).
Determination of CB-153 and p,p´-DDE.
Serum concentrations of CB-153 and
p,p´-DDE were determined using solid phase
extraction (SPE) and on-column degradation
of lipids, followed by analysis with gas chro-
matography–mass spectrometry (Rignell-
Hydbom et al. 2004). The relative standard
deviations, calculated from samples analyzed
in duplicate on different days, was < 18% for
CB-153 and < 11% for p,p´-DDE. The
detection limits were 0.05 ng/mL for CB-153
and 0.1 ng/mL for p,p´-DDE. The analyses of
CB-153 and p,p´-DDE were part of the
Round Robin intercomparison program
(H. Drexler, Institute and Out-Patient Clinic
for Occupational, Social and Environmental
Medicine, University of Erlangen-Nuremberg,
Germany) with analysis results within the tol-
erance limits. The POP concentrations were
adjusted for serum lipids analyzed with enzy-
matic methods, and the interassay coefﬁcients
of variation (CVs) were 1.5–2.0% (Jonsson
et al. 2005).
SPE-HPLC fractionation of the serum
samples. To obtain the serum fraction con-
taining the actual mixture of bioaccumulated
lipophilic POPs, we performed an SPE fol-
lowed by high performance liquid chromatog-
raphy (HPLC) fractionation on 3.6 mL serum
(Bonefeld-Jørgensen et al. 2006; Hjelmborg
et al. 2006). The first HPLC fraction (F1:
0.00–5.30 min, protected from light in brown
tubes), which included most POPs while leav-
ing out the endogenous hormones (Hjelmborg
et al. 2006), was evaporated to near dryness
and frozen for later AR-CALUX analysis. To
verify that the endogenous hormones were
separated from F1 but present in F2.1
(5.30–12.0 min), we performed AR-CALUX
analyses of the F1 and F2.1 SPE-HPLC frac-
tions of different male serum.
Batches of serum from the blood bank of
Aarhus Sygehus (Denmark) were combined
and distributed into 3.6-mL portions and
stored at –80°C. This was done for male
(KHM) and female (KHF) serum; on a
weekly basis, one sample from each sex was
processed by the SPE-HPLC method in par-
allel with the project samples; these samples
served as serum controls for this cleanup pro-
cedure. The mean intra-CV (coefficient of
variation within the same assay) of these
serum controls was < 11%, and the inter-CV
(day to day) was < 31% (n = 12). 
On the day of analyses, the SPE-HPLC F1
fractions (project samples and serum controls)
were dissolved as previously described
(Bonefeld-Jørgensen et al. 2006; Hjelmborg
et al. 2006). The serum samples were analyzed
randomly, and we attempted to analyze serum
from different study groups in each indepen-
dent assay.
AR-CALUX assay. AR transactivity was
determined in Chinese Hamster ovary cells
(CHO-K1) by transient cotransfection with
the MMTV-LUC reporter vector (kindly pro-
vided by R.M. Evans, The Salk Institute for
Biological Studies, La Jolla, CA, USA) and
the AR expression plasmid pSVAR0 (kindly
provided by A.O. Brinkmann, Erasmus
University, Rotterdam, the Netherlands). 
The synthetic AR agonist methyltrienolone
(R1881) and the antagonist hydroxyﬂutamide
(HF; Mikromol GmbH, Luckenwalde,
Germany), both protected from the light, were
used as dose–response controls in each assay.
We determined the EC50 (median effective
concentration) of R1881 (0.025 nM) and the
IC50 (median inhibitory concentration) of HF
(58.5 nM) using the Chapman, 4 parameters
equation in Sigma Plot (SPSS Inc., Chicago,
IL, USA). The R1881 EC50 served as a positive
control on each separate plate and was used to
determine the competitive effect of HF and the
F1 serum fraction. The solvent controls
(± R1881 EC50) consisted of samples treated
the same as the SPE-HPLC F1 fractions, but
without the serum. The solvent control and
the R1881 EC50 solvent control had inter-CVs
of ≤ 11% (n = 13) and ≤ 13% (n = 13), respec-
tively. The xeno-AR activity was determined in
the F1 serum fraction alone (XAR), and the
competitive xeno-AR activity (XARcomp) was
determined upon co-treatment of cells with F1
and R1881 EC50.
We performed the reporter gene assay as
described by Birkhoj et al. (2004) with minor
modiﬁcations: The transfection was carried out
with 100 ng DNA, and the transfection
reagent Fugene was not removed before appli-
cation of the samples; the dissolved SPE-
HPLC F1 samples ± R1881 EC50, in triplicate,
were added to the cells in parallel with the
described controls (KHM, KHF, R1881 EC50,
and solvent ± R1881 EC50). Cell lysis,
Krüger et al.
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measurements, were performed as described by
Bonefeld-Jørgensen et al. (2006). 
The luciferase activity was corrected to
the cell protein content and expressed in rela-
tive luciferase units per microgram protein
(RLU/protein). If one of the triplicate values
deviated > 30% from the other two values,
the mean was calculated from two wells only.
To standardize the data for transfection efﬁ-
ciency, the XAR and XARcomp activity data
was normalized to the respective solvent con-
trols, which were set to 1. Finally, the data
was given as activity per milliliters of serum,
and the values of the solvent controls were
3.13 RLU/mL serum.
Statistical analysis. We checked data dis-
tribution using Q-Q plots. The XAR and
XARcomp activities and lipid-adjusted
CB-153 and p,p´-DDE were natural-log (ln)
transformed to improve normality, and the
statistical analyses were performed on the con-
tinuous ln-transformed data. 
We performed the comparisons of means
of XAR and XARcomp among the different
study groups using one-way analysis of vari-
ance (ANOVA). If signiﬁcant differences were
observed between the groups, multiple com-
parison ad hoc tests were performed using the
least-significant difference (LSD) pair-wise
multiple comparison test for variables with
equal variance (p > 0.05) and Dunnett’s T3
test for variables with an unequal variance
(p ≤ 0.05). We tested for homogeneity of vari-
ance using Levene’s test.
We used Spearman’s rank correlation to
evaluate associations of the xenoandrogenic
activity both to POP markers and to endoge-
nous serum estradiol and testosterone (total
and free), which served as method veriﬁcation
that the sex hormones were excluded from the
F1 fraction. The overall association between
POP markers and xenoandrogenic activity
across the study groups were evaluated by
comparing the regression lines for each study
group using multiple linear regression analysis.
In the ﬁrst step, we investigated whether the
associations across the study groups are
homogenous. If this hypothesis was accepted,
we used a model with parallel regression lines
to analyze common slopes and intercepts of
the regression lines for each study group. If
both the hypothesis of a common slope and
the hypothesis of a common intercept were
accepted, indicating that the regression lines
are equal, the data for the study groups
could be combined. However, if one or both
of the hypotheses were rejected, the regression
lines are not equal and the data cannot be
combined.
Our hypothesis was that a potential deter-
minant of POP bioaccumulation might also
be a potential determinant for serum xeno-
androgenic activity. From the literature and
from an assessment of the total INUENDO
study populations (Jonsson et al. 2005; Toft
et al. 2005), age and seafood intake are known
determinants affecting the POP serum level.
We also evaluated lifestyle characteristics
(Table 1) as potential determinants of XAR
and XARcomp activities. Using multivariate
linear regression to evaluate the impact of
POP biomarkers and potential determinants
on XAR/XARcomp, blocks of variables,
together with either CB-153 or p,p´-DDE,
were entered as follows: In block I, age and
seafood intake were included in the model;
and in block II, age, seafood, smoking status
(smoked ever, yes/no), body mass index
(BMI), and alcohol and coffee intake were
included. Because many values of the potential
determinants were missing, the number of
available observations in the confounder
analyses are much smaller than in the unad-
justed analysis on the full data set (full data
set, n = 250; block I of confounders, n = 192;
block II, n = 104). Therefore, we performed
the analysis only on the block II data set
(n = 104) containing information about all the
determinants. The statistical analysis was per-
formed in SPSS 10.0 (SPSS Inc, Chicago, IL,
USA). We considered a p-value ≤ 0.05 to be
statistically signiﬁcant.
Results
Correlations between xenoandrogenic serum
activity and endogenous hormones: method
verification. AR-CALUX analysis of the
SPE-HPLC serum fractions F1 and F2.1
showed that the F2.1 fraction (containing
androsterone and testosterone,) elicited
signiﬁcantly higher XAR activity than the F1
fraction (free of endogenous hormones)
(Figure 1A). This indicates that the endoge-
nous androgens were excluded from the F1
fraction. The XAR activity of the KHM and
KHF F1 serum controls did not differ signiﬁ-
cantly from the solvent control, whereas the
XARcomp activity of KHM was signiﬁcantly
lower than the R1881 EC50 solvent control
(Figure 1B).
We found no correlation between XAR
and endogenous blood testosterone (free and
total) and estradiol for the combined data of
the study groups (data not shown).
Basic characteristics of the study groups.
Demographic and lifestyle factors (Table 1)
that may potentially inﬂuence the AR-medi-
ated activities of the study groups were similar
with those obtained for the total INUENDO
study population (Toft et al. 2005). The levels
of CB-153 and p,p´-DDE (Table 2) were in
the same range as for the main study groups
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Table 1. Characteristics of the men in the study groups.
Greenland Warsaw Sweden Kharkiv All
Age (years)
No. 35 81 58 79 253
Median (SD) 30 (6.0) 30 (4.1) 44 (9.8) 25 (5.4) 30 (9.6)
Min–max 18–46 24–46 24–68 16–45 16–68
BMI (kg/m2)
No. 36 80 59 80 255
Median (SD) 26 (3.7) 25 (3.4)  26 (2.8) 23 (3.1)  25 (3.3)
Min–max 19–35 19–38 22–36 19–36 19–38 
Alcohol (drinks/week)
No. 23 71 61 155
Median (SD) 2.8 (4.6)  4.0 (6.5) NA 3.0 (2.9) 3.0 (5.2)
Min–max 0–31 0–30 0.5–15 0–31 
Smoking 
Percent (No.) 86 (35) 49 (81) 64 (59) 82 (81) 68 (256)
Seafood (days/week)
No. 36 76 80 192
Median (SD) 1.5 (1.5)  1.0 (1.2) NA 4.0 (1.2) 2.0 (1.6)
Min–max 0–7 0–9 1–9 0–9 
Coffee (cups/day)
No. 34 70 35 139
Median (SD) 3.0 (4.0) 1.3 (1.2)  NA 2.0 (1.2) 2.0 (2.5)
Min–max 0–12 0–6 1–7 0–12 
Total T (nmol/Ll)
No. 11 69 58 82 220
Median (SD) 15 (4.1) 13 (4.3) 11 (5.0) 18 (4.5) 15 (5.3)
Min–max 10–23 6–23  4–28  8–31  4–31 
Free T (nmol/L)
No. 11 69 58 82 220
Median (SD) 0.32 (0.07) 0.30 (0.08) 0.24 (0.08) 0.39 (0.10) 0.30 (0.11)
Min-max 0.11–0.49 0.15–0.51  0.09–0.50 0.20–0.64 0.09–0.64 
Estradiol (nmol/L)
No. 11 69 58 82 220
Median (SD) 59 (16) 70 (32) 64 (21) 79 (24) 71 (27)
Min–max 31–85 45–297 25–154 33–144 25–297 
Abbreviations: max, maximum; Min, minimum; NA, not available; T, testosterone. No. is the number of individuals with
data for the speciﬁc demographic and lifestyle characteristics. (Jonsson et al. 2005) as were the inter-
correlations between serum concentration of
CB-153 and p,p´-DDE (Greenland: rS = 0.93;
Sweden: rS = 0.68; Kharkiv: rS = 0.52;
Warsaw: rS = 0.35).
The XAR activity of the study groups did
not differ significantly (ANOVA, p = 0.51),
reﬂecting that the percentage of serum extracts
with increased XAR activity (Table 2) was
similar for the four study groups (25–35%). 
One-way ANOVA (p < 0.001) followed
by multiple comparison of means showed that
the XARcomp activity was signiﬁcantly differ-
ent between the study groups (LSD test,
p < 0.001) except for Sweden and Warsaw
(LSD test, p = 0.91). The four study groups
also differed with respect to the percentage of
serum samples with increased or decreased
XARcomp activity (Table 2): in Greenland
22% and 3%, and in Kharkiv 0% and 50%,
respectively. For the Warsaw and Swedish
study groups, 21% and 8%, respectively, of
the serum samples showed a decreased
XARcomp activity. For the European study
groups, the highest level of p,p´-DDE was
found in Kharkiv, and this study group had
the highest percentage of serum samples
(50%) with decreased XARcomp activity. The
lowest level of p,p´-DDE was observed in the
Swedish study group, the group in which we
found the lowest percentage of serum samples
(8%) with decreased XARcomp activity. 
Statistical analysis of xenoandrogenic
activity and POP markers. We found no cor-
relations between the POP markers and either
XAR or XARcomp in the four study groups
(data not shown). Adjusting for seafood and
age (block I) and for seafood, age, smoking
status, BMI, alcohol, and coffee (block II) in a
multiple linear regression model did not
change the results (data not shown). 
Multiple regression analysis of both
response variables (XAR and XARcomp)
showed homogeneity of slopes between study
groups and the POP markers (Table 3).
Furthermore, in the model with parallel regres-
sion lines, we found common slopes and inter-
cepts for XAR against CB-153 and p,p´-DDE
(Table 3), which support the ANOVA analysis
showing no difference between the study
groups. However, no significant correlations
were observed when data were combined (data
not shown). For XARcomp against CB-153
and p,p´-DDE, we found common slopes but
different intercepts (Table 3). Thus, the differ-
ence in XARcomp activity between the study
groups (ANOVA, p < 0.001) still existed after
adjustment for CB-153 and p,p´-DDE.
In the European study groups, the percent-
age of serum samples with decreased XARcomp
activity followed the level of p,p´-DDE
(Kharkiv > Warsaw > Sweden); therefore, we
tried to analyze the combined European data.
We observed a signiﬁcant negative association
(rS = –0.21; p = 0.001) between XARcomp
and p,p´-DDE across the combined European
study groups. In the multiple regression
analysis of the combined European study
groups, the hypothesis of a common intercept
was rejected (data not shown).
Discussion
In the present study we found that a)t h e
XARcomp activity in the Inuits was signifi-
cantly different from that in the European
study groups; b) the percentage of serum
samples with decreased XARcomp activity in
the European study groups [Kharkiv (50%) >
Warsaw (21%) > Sweden (8%)] positively fol-
lowed the p,p´-DDE serum level; c) the XAR
activity was not signiﬁcantly different between
the study groups; and d) there were no signiﬁ-
cant correlations between xeno-AR activities
and any of the two POP markers. 
It is well documented, both in vitro and
in vivo, that p,p´-DDE is an AR antagonist
(Araki et al. 2005; Gray et al. 1999; Roy
et al. 2004; Vinggaard et al. 1999), which is
consistent with the observed decreased
XARcomp activities in the European groups.
Interestingly, in a parallel INUENDO study,
the fecundability among couples in Kharkiv
Krüger et al.
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Table 2. Xenoandrogenic serum activities and lipid-adjusted serum levels of CB-153 and p,p´-DDE.
Greenland Warsaw Sweden Kharkiv All
XAR RLU/mL serum
No. 37 83 59 82 261
Mean ± SE  3.85 ± 0.14 3.93 ± 0.21 3.83 ± 0.13 3.57 ± 0.09 3.78 ± 0.08
Percent increased 35 25 34 26 28
Percent decreased 3 5 5 2 4
XARcomp RLU/mL serum
No. 37 83 59 82 261
Mean ± SE  4.05 ± 0.18 2.99 ± 0.07 3.01 ± 0.10 2.25 ± 0.06 2.91 ± 0.06
Percent increased 22 7 10 0 8
Percent decreased 3 21 8 50 26
CB-153 (ng/g lipid)
No. 35 83 58 76 252
Mean ± SE  262 ± 34 20 ± 2 238 ± 27 58 ± 5 115 ± 10
p,p´-DDE (ng/g lipid)
No. 35 83 58 76 252
Mean ± SE  678 ± 83 653 ± 37 299 ± 39 1,130 ± 77 718 ± 35
The percent increased and percent decreased indicate the percentage of serum samples (of the total number of samples)
that elicited a signiﬁcant increase or decrease in XAR/XARcomp activity, respectively. In each independent assay, the
signiﬁcant activity differences between the triple F1 fraction determinations and their respective solvent controls (per-
cent increased and percent decreased) were determined by the Student’s f-test and t-test using Microsoft Excel
(Microsoft Corporation, Redmond, WA, USA) (p ≤ 0.05).
Table 3. Multiple regression of the combined study group data.
Exposure Homogeneity Common slope Common Adjusted
Response variable variable of slopes (p-value) estimate (SE); p-value intercept R2 (p-value)
XAR (n = 252) CB-153 0.63 0.003 (0.02); 0.91 0.45 0.00
p,p´-DDE 0.96 –0.001 (0.03); 0.98 0.54 0.00
XARcomp (n = 252) CB-153 0.92 0.01 (0.02); 0.80 < 0.001* 0.36
p,p´-DDE 0.56 0.05 (0.03); 0.10 < 0.001* 0.37
Response and exposure variables are ln-transformed. Test for homogeneity of association between exposure variable
and outcome variable across study groups, p > 0.05; hypothesis of homogeneity accepted. Estimated common slope
across study groups assuming homogeneity of slopes, p > 0.05; hypothesis of a common slope accepted. Test for a com-
mon intercept across study groups assuming a common slope, p > 0.05; hypothesis of a common intercept accepted.
Adjusted R2 assuming a common slope, adjusted for degrees of freedom. 
*Statistically signiﬁcant (p ≤ 0.05).
Figure 1. Veriﬁcation of the HPLC procedure. (A) XAR activity of the HPLC fractions F1 (0.00–5.30 min; with-
out endogenous hormones) and F2.1 (5.30–12.0 min; with endogenous hormones) from three different
males were determined in the AR-CALUX assay. (B) Mean ± SE of the F1 fraction of KHM and KHF serum
controls alone (XAR; n = 12) or in the presence of R1881 EC50 (XARcomp; n = 9). 
*XAR activity of the F2.1 fraction significantly higher than for the F1 fraction. #Significantly lower than the R1881 EC50
solvent control. 
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KHFwas lower than among couples from the other
study groups (Toft et al. 2005). Furthermore,
the lowest sperm motility in semen samples
was found in the Kharkiv samples, compared
with the three other study groups (Toft et al.
2005). However, in the present study, we
found high p,p´-DDE levels in serum in the
Inuits, who also had the highest percentage
of serum samples (22%) with increased
XARcomp activity. These data from the dif-
ferent ethnic groups could be caused by a dif-
ferent composition of serum POPs, despite
the high amounts of p,p´-DDE in Inuits. In
parallel INUENDO studies that investigated
the xenoestrogenic (Bonefeld-Jørgensen et al.
2006) and dioxin-like (Long et al. 2006)
activities in human serum samples, signiﬁcant
differences between Inuits and the European
study groups were also observed. In addition
to a different exposure pattern, dietary habits
and/or lifestyle factors and the genetic differ-
ence between Inuits and Caucasians (de Maat
et al. 1999) may also be taken into account
when evaluating the observed differences.
We found no correlations between the
xeno-AR activities and the two POP markers.
This is in accordance with previous studies in
human adipose tissue or serum that reported
the lack of correlation between several sus-
pected endocrine disruptors and estrogenic
activities (Fernandez et al. 2004; Ibarluzea
et al. 2004; Rasmussen et al. 2003; Rivas
et al. 2001). Furthermore, CB-153 might not
be optimal as a global exposure marker for
POPs because the pattern of distribution of
noncoplanar and coplanar CBs can differ
geographically depending on occupational
and/or nonoccupational exposures (Dewailly
et al. 1994).
We rejected the hypothesis of a common
intercept for XARcomp activities in the mul-
tiple linear regression model. However, when
we assumed a common intercept, a signiﬁcant
negative correlation was found between the
XARcomp activity and p,p´-DDE for the
combined European study groups. This sug-
gests that p,p´-DDE might be involved in the
decreased XARcomp activity in a concentra-
tion-dependent manner in the European
study groups. 
The total androgenic bioactivity in whole
human serum samples has been investigated
in cell-based reporter gene assays (Paris et al.
2002; Raivio et al. 2001; Roy et al. 2006);
these assays represented reliable methods for
determining androgenic activities in biologi-
cal samples. However, these studies deter-
mined the total androgenic bioactivity in
whole human serum, which contained the
endogenous hormones. In contrast, our assay
determines the xenoandrogenic activity of the
serum fraction of bioaccumulated POPs only.
The inter-CV was ≤ 13% for the solvent
controls and < 31% for the serum controls
(KHM and KHF). However, our CVs are
within the range observed in other in vitro
studies (Korner et al. 2004) using reporter gene
assays (the CV for the androgen control was
22% in stably transfected human prostate
adenocarcinoma PC-3 cells, 30% in transiently
transfected CHO-K1 cells, and 57% in stably
transfected human breast carcinoma MDA-
kb2 cells).The higher CV of the serum controls
compared with the solvent controls in our
study can be explained by further variations
introduced by the SPE-HPLC extraction. 
The R1881 EC50 value of 0.025 nM in
our assay was somewhat lower than that seen
in other reporter gene assays using other cell
lines (Blankvoort et al. 2001; Christiaens
et al. 2005; Korner et al. 2004; Lemaire et al.
2004). In stable transfected PC3 cells
(PALM), Lemaire et al. (2004) found an
EC50 for R1881 of 0.066 nM in one study,
whereas Korner et al. (2004), who also used
PALM cells, reported an EC50 of 0.11 nM.
Thus, even in the same cell line, the EC50
value can vary between laboratories. 
Hjelmborg et al. (2006) previously
showed that the F1 fraction, analyzed for
xenoandrogenic effects, included PCB-180,
PCB-126, PCB-81, endosulfan, PCB-153,
PCB-138, bisphenol A dimethacrylate,
o,p´-DDT, 4n-nonylphenol, 4-octylphenol,
4-OH-PCB-121, vinclozolin, bisphenol A,
butyl hydroxy anisole, and methiocarb. The
F2.1 fraction contained the endogenous hor-
mones pregnenolone, androsterone, proges-
terone, estrone, and testosterone, as well as
the pesticides fenarimol and prochloraz
(Hjelmborg et al. 2006). To verify our SPE-
HPLC AR-CALUX method, we analyzed the
F2.1 serum fraction in parallel with the F1
serum fraction free of endogenous hormones.
The significantly higher XAR activity of the
F2.1 fraction compared with the F1 fraction
indicates that the endogenous hormones,
which are capable of activating the AR, are
present in F2.1 but not in F1 fractions.
Furthermore, the XAR activity of the KHM
F1 fraction did not differ from the solvent
control or KHF. Because total androgenic
bioactivity is higher in men than in women
(Paris et al. 2002), a signiﬁcantly higher XAR
activity for KHM, compared with KHF,
would have been expected if the endogenous
hormones were present in the F1 serum frac-
tion. Vinggaard et al. (1999) previously
showed that estradiol is able to compete with
R1881 for transactivation of AR in an AR-
CALUX assay similar to the one used in the
present study. Therefore, we investigated cor-
relations between XAR and the sex hormones
testosterone (total and free) and estradiol. We
found no correlations between XAR and the
sex hormones, conﬁrming optimal separation
of the endogenous hormones from the SPE-
HPLC F1 fraction. In investigations of total
androgen bioactivity in whole human serum
samples, including endogenous hormones,
Raivio et al. (2001) and Roy et al. (2006)
found signiﬁcant correlations between serum
testosterone levels and androgen bioactivity.
In a parallel study using the same SPE-HPLC
approach, Bonefeld-Jørgensen (et al. 2006)
observed no correlations between the endoge-
nous hormones in serum and the xeno-
estrogenic activity of the F1 serum fraction;
this further confirms the separation of the
endogenous hormones.
We used the serum (KHM, KHF) from
Danish individuals as controls for the SPE-
HPLC cleanup procedure. The XAR data of
the serum controls from 12 independent
assays were not signiﬁcantly different from the
solvent control, indicating that no compounds
present in the serum sample were able to acti-
vate AR activity. However, compared with the
XARcomp activity of the R1881 EC50 solvent
control, the XARcomp activity of KHM was
signiﬁcantly lower but that of KHF was not.
Thus the SPE-HPLC F1 fraction seems to
contain a mixture of bioaccumulated
lipophilic POPs that differ between samples
and are able to interfere with the R1881-
induced AR activity in the CALUX assay. 
To our knowledge, this is the first study
to determine the integrated biological activity
of AR-active lipophilic compounds in their
actual mixture in serum; therefore, potential
determinants for the activity were unknown.
We hypothesized seafood, age, smoking sta-
tus, BMI, alcohol, and coffee to be potential
determinants of AR activity. However, the
data did not change upon adjustment for
these potential determinants. A different pos-
sibility is that other exogenous chemicals
might confound the obtained data and that
the two selected POP markers do not ade-
quately reﬂect and/or represent the chemicals
primarily responsible for the determined
xenoandrogenic effects.
Conclusions
We found a signiﬁcantly higher percentage of
serum samples with decreased XARcomp activ-
ity for the Kharkiv study group, which had the
highest p,p´-DDE level of the four study
groups. Moreover, in the European study
groups, the percentage of serum samples with
decreased XARcomp activity followed the
p,p´-DDE serum levels. In the Inuit study
group, we found a signiﬁcantly higher percent-
age of serum samples with increased XARcomp
activity compared with the European study
groups. No consistent correlations were found
between XAR/XARcomp and the two POP
proxy markers for the individual study groups
or across study groups, suggesting that neither
CB-153 nor p,p´-DDE alone can predict the
xenoandrogenic activity of the serum samples
included in the present study.
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activity would differ between the study
groups with different POP proﬁles, and that
the two selected POP markers would correlate
to the xenoandrogenic activities. The first
hypothesis was accepted: The differences in
XARcomp serum activity between the study
groups seem to reﬂect differences in chemical
exposure profiles, genetics, and/or lifestyle
factors. However, the second hypothesis was
rejected; therefore, the selected POP markers
could not be used as biomarkers of exposure
to determine the xenoandrogenic effects.
The present ex vivo biomarker AR-
CALUX activity assay may contribute to the
insight of the impact of the total bio-
accumulated EDCs geographically, which is
difficult to predict on the basis of chemical
analysis alone. However, the determined
XAR/XARcomp activities of the serum frac-
tion containing lipophilic POPs may fail to
detect effects accomplished by hydrophilic
compounds or effects through other receptors
or other mechanisms. 
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